Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2014

View Archived Issues

Structure-based discovery of novel ITK inhibitors, GNE-9822 lead identified

A potent mGluR5 PAM shows promise in rodent cognition models

Results of a phase I dose-escalation study of a chikungunya virus vaccine

VX-787, first-in-class PB2 influenza polymerase inhibitor

arGEN-X reports preclinical data for ARGX-113

Glenmark Pharmaceuticals to begin IND-enabling studies of new bispecific antibody

Bristol-Myers Squibb and Celgene to evaluate immunotherapy/chemotherapy combination

Amicus Therapeutics reports phase III data for migalastat in Fabry disease

Pfizer and Crohn's & Colitis Foundation of America form IBD collaboration

Aeolus files IND for acute radiation syndrome candidate AEOL-10150

Illumina forms multiple collaborations for oncology genomics analysis

AM-9514, a GK activator with good pharmacokinetic profile in vivo

KalVista Pharmaceuticals confirms first-in-human trial of KVD-001

Potential AD treatment activates TGF-beta signaling pathway in the brain

Vertex Pharmaceuticals patents novel sodium channel blockers

Toyama designs novel antifungal agents

Researchers at Bayer Schering Pharma synthesize new products for cancer

Hanmi Pharm enters into agreement with Luye Pharma Group for poziotinib

Korean scientists present new anti-C5 MAbs

ViaCyte and Janssen enter rights agreement for type 1 diabetes cell therapy

Baxter's PEGylated rFVIII meets primary endpoint in phase III trial

Apixaban granted FDA approval for DVT and PE

EMA accepts Basilea Pharmaceutica's isavuconazole MAA for review

Lilly's ixekizumab superior to etanercept in phase III plaque psoriasis trials

Auxilium and BioSpecifics report positive data from phase IIa trial of Xiaflex

GSK to conduct phase II study of GSK-2862277 to prevent acute lung injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...